CAMBRIDGE, Mass., April  27, 2026  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of

FULC

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Fulcrum Therapeutics Names Josh Lehrer to Board Enhancing Drug Development Expertise

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CAMBRIDGE, Mass., April  27, 2026  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Fulcrum Therapeutics has appointed Josh Lehrer to its Board of Directors, bringing valuable experience in rare disease drug development. His previous role in the approval of Oxbryta for sickle cell disease is particularly significant as Fulcrum advances pociredir, which aims to improve treatment options for this condition, potentially boosting investor confidence.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Josh Lehrer appointed to Fulcrum&#039;s Board of Directors.</li><li>Lehrer brings extensive drug development expertise in rare diseases.</li><li>He previously contributed to the approval of Oxbryta for sickle cell disease.</li><li>Lehrer will support the advancement of Fulcrum&#039;s pociredir therapy.</li><li>Pociredir aims to treat sickle cell disease, leveraging PIONEER trial results.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Graphite Bio, Inc. (GRPH)</strong>: Lehrer&#039;s previous role may influence investor sentiment towards Fulcrum.</li><li><strong>Global Blood Therapeutics (GBT)</strong>: Approval of Oxbryta shows Lehrer&#039;s capability in advancing therapies.</li><li><strong>Marea Therapeutics (MREA)</strong>: Lehrer&#039;s leadership experience may enhance Fulcrum&#039;s strategic focus.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments as it involves strategic leadership changes that may influence Fulcrum&#039;s direction and operational effectiveness, impacting its potential growth in the hematology segment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lehrer&#039;s extensive background may expedite pociredir&#039;s regulatory approval process.</li><li>Fulcrum&#039;s advancements in sickle cell disease treatments could attract additional investment.</li><li>Favorable results from the PIONEER trial may positively impact stock valuations.</li><li>Lehrer’s reputation may enhance Fulcrum’s partnerships and collaborations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Josh Lehrer has over 20 years of clinical development experience.</li><li>He was previously CEO of Graphite Bio until September 2023.</li><li>Lehrer led the development of Oxbryta for sickle cell disease.</li><li>Pociredir is designed to increase fetal hemoglobin expression.</li><li>Fulcrum targets rare hematological disorders through advanced drug development.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying FULC shares in anticipation of positive developments in pociredir&#039;s progress.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>CAMBRIDGE, Mass., April  27, 2026  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>&#xAE; </sup>(Fulcrum) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director.</p>  <p>Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development experience across all stages of drug development. He currently serves as Chief Executive Officer and a member of the board of directors of Marea Therapeutics, a clinical-stage biotechnology company. Previously, Dr. Lehrer served as President and Chief Executive Officer of Graphite Bio, Inc. from April 2020 until September 2023. Prior to that, he was the Chief Medical Officer at Global Blood Therapeutics where he oversaw the development and approval of Oxbryta<sup>&#xAE;</sup> (voxelotor) for the treatment of sickle cell disease. Earlier in his career, Dr. Lehrer held clinical development and business development roles at Genentech.</p>  <p>"We are delighted to welcome Josh to Fulcrum's Board of Directors," said Alex C. Sapir, President and Chief Executive Officer of Fulcrum Therapeutics. "Josh brings deep expertise in rare disease drug development and a strong track record advancing transformative therapies, including his leadership in the development and approval of Oxbryta for patients with sickle cell disease. His experience will be invaluable as we continue advancing pociredir and our broader benign hematology pipeline."</p>  <p>"I spent more than a decade working to develop new therapies for patients with sickle cell disease, and the need for effective, orally available treatments remains significant," said Dr. Lehrer. "Fulcrum is advancing a promising approach with pociredir, supported by results from the PIONEER trial, and I look forward to working alongside the board and management team to help bring this therapy forward for patients."</p>  <p>Dr. Lehrer received an A.B. in Biochemical Sciences from Harvard University and a Master of Philosophy in Biological Sciences from the University of Cambridge. He earned his Doctor of Medicine from the University of California, San Francisco and completed his residency in internal medicine at UCSF, followed by postdoctoral fellowship in cardiovascular medicine at Stanford University.</p>  <p><strong>About Fulcrum Therapeutics</strong><br></br>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=g1WvfZcPFfo5WASMrWx5ouVn526Ud4LbU7BZte1kO8-iF8I2zyNmWjm9iQlGqRATC49YvP70_0TpDUXE3R_9KACQb-XSdSRcpGbQLq-TFCQ=" rel="nofollow" target="_blank">www.fulcrumtx.com</a> and follow us on X (@FulcrumTx) and LinkedIn.</p>  <p><strong>Contact: </strong><br></br><br></br>Kevin Gardner<br></br>LifeSci Advisors, LLC<br></br>kgardner@lifesciadvisors.com<br></br>617-283-2856</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5NjczOSM3NTU1MDMxIzIxODM1NDI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDE0ZmM1NjUtZDYwMS00NTc5LTk0MDAtZThmYWZiMjQ4M2YyLTExOTUxMDAtMjAyNi0wNC0yNy1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252"><img src="https://ml.globenewswire.com/media/3434fc83-4bcf-4d3c-ae26-23e5b1fd4252/small/fulcrum-logo-primary-full-color-rgb-large-png.png" border="0" width="150" height="36" alt="Primary Logo"></img></a></p>

Fulcrum Therapeutics has appointed Josh Lehrer to its Board of Directors, bringing valuable experience in rare disease drug development. His previous role in the approval of Oxbryta for sickle cell disease is particularly significant as Fulcrum advances pociredir, which aims to improve treatment options for this condition, potentially boosting investor confidence.

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News